Evidence map›Paper›PMID 40574277›Full record

ArticleJournal of pathology and translational medicine2025

Acquired aberrant partial CD3 expression in recurrent Epstein-Barr virus-negative solitary plasmacytoma of tonsil.

Chenchen Niu, Dong Ren, Truc Tran, Ashley Gamayo, Sherif Rezk, Xiaohui Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pathology and translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chenchen NiuDepartment of Pathology & Laboratory Medicine, University of California Irvine Medical Center (UCIMC), Orange, CA, USA.
Dong RenDepartment of Pathology & Laboratory Medicine, University of California Irvine Medical Center (UCIMC), Orange, CA, USA.
Truc TranDepartment of Pathology & Laboratory Medicine, University of California Irvine Medical Center (UCIMC), Orange, CA, USA.
Ashley GamayoDepartment of Pathology & Laboratory Medicine, University of California Irvine Medical Center (UCIMC), Orange, CA, USA.
Sherif RezkDepartment of Pathology & Laboratory Medicine, University of California Irvine Medical Center (UCIMC), Orange, CA, USA.
Xiaohui ZhaoDepartment of Pathology & Laboratory Medicine, University of California Irvine Medical Center (UCIMC), Orange, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aberrant expression of specific T-cell maker CD3 in B-cell neoplasms can be a potential diagnostic pitfall leading to a misclassification of cell lineage. Here, we report a case of recurrent solitary plasmacytoma with new aberrant expression of CD3. The neoplastic plasma cells of the recurrent tumor were kappa restricted, positive for CD138, MUM1, negative for CD20, cyclin D1, and Epstein-Barr virus. CD79a was positive in majority of the tumor cells, except for a small focus which was strongly positive for CD3, but negative for other T-cell markers (CD2, CD5, CD7, CD4, and CD8) and CD56. The neoplastic plasma cells of the original tumor were negative for CD3. To the best of our knowledge, only one case of recurrent plasmacytoma with aberrant expression of CD3 has been published, which revealed disease progression in the recurrence. However, we did not observe morphologic evidence of disease progression in our case.

Indexed as

CD3Neoplasm, plasma cellPlasmacytomaT-cell antigen

Identifiers

PMID40574277
PMCPMC12264490

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.